Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Magazine

Table: Where the R&D Dollars Go


1. A LONG ROAD

The path from spotting an interesting gene target to getting a drug on the market can take a dozen years. So half of the average estimated $300 million to $500 million R&D "cost" per drug is simply opportunities lost to invest the money elsewhere.

2. EXTENSIVE TESTS

Companies must test thousands of compounds on cells to spot a few with the desired effects--and many of those will be toxic. Speeding this process, however, could dramatically reduce R&D costs by cutting development time.

3. HUMAN SURPRISES

Only about one in 10 drugs promising enough to test in humans is safe and effective enough to make it to market. Since the failures eat up roughly half of direct R&D expenditures, cutting the failure rate would also slash overall costs.

4. CHEAP PILLS

Many drugs cost just a few cents per pill to make. So in theory, drugmakers should be able to boost production and sell on the cheap to developing nations without threatening future research--and still make marginal profits.


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus